Research in contextEvidence before this studyGenetic mutations in key biomarkers are known to predict outcomes and response to treatment in metastatic colorectal cancer. Concordance in these biomarkers between the primary and metastatic sites is an important factor to consider with both diagnostic and therapeutic implications. We systematically reviewed all published comparative studies reporting on biomarker concordance between primary and metastatic sites. These studies were identified using PubMed, MEDLINE, Ovid, Embase, Cochrane, and Google Scholar databases. Biomarkers that were studied included KRAS, BRAF, NRAS, PIK3CA and PTEN, among others.Added value of this studyThis study provides a comprehensive review of the concordance rates of genetic biomarker mutations between primary and metastatic sites in colorectal cancer. This allows us to quantify the predictive value of a metastatic site biopsy in determining the biomarker mutation status of the primary colorectal cancer. It also presents what is currently known about biomarker concordance by metastatic site.Implications of all the available evidenceThis study demonstrates a high genetic concordance rate between primary colorectal cancers and their liver/lung metastases. Despite peritoneal metastases being the third most common site, little remains known about their concordance with the primary colorectal cancer. There is currently no evidence that multiple metastatic site biopsies will provide benefit, with single sites sufficient for diagnosis and biomarker profiling provided adequate samples can be taken. This has important implications for reducing the time to diagnosis, commencement of treatment, and cost.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Approximately 1.4 million patients per annum worldwide are diagnosed with colorectal cancer (CRC). Metastatic (stage IV) disease at presentation results in a 5-year overall survival (OS) of 14% \[[@bb0005],[@bb0010]\], whilst 50% of patients undergoing surgery with curative intent develop metastatic disease within 5 years \[[@bb0015]\]. The most commonly reported sites include lymph nodes (35--40%) \[[@bb0020]\], liver (50--60%) \[[@bb0025],[@bb0030]\], lung (10--30%) \[[@bb0035]\], and peritoneum (5--20%) \[[@bb0040], [@bb0045], [@bb0050]\].

Advances in biological therapies such as anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab and panitumumab) have resulted in biomarkers being used to target metastatic CRC (mCRC) \[[@bb0055]\]. KRAS is a key proto-oncogene downstream of EGFR and is activated in up to 50% of sporadic mCRC patients, with 95% of activations occurring in codons 12/13 of exon 2 \[[@bb0060]\]. Importantly, KRAS exon 2--4 mutations (involving codons 12, 13, 161, 117 & 146) demonstrate a significantly lower response to cetuximab and panitumumab \[[@bb0065],[@bb0070]\]. Some studies have also indicated that KRAS mutations may confer resistance to bevacizumab \[[@bb0075],[@bb0080]\]. The extended RAS family of oncogenes includes NRAS, with exon 2--4 mutations occurring in 3--5% of CRC\'s and similarly resulting in a lower response \[[@bb0085],[@bb0090]\]. BRAF, a RAF gene kinase and immediate downstream effector of KRAS, shows mutations in nearly 10% of colorectal adenocarcinomas and is also a strong negative prognostic marker, predicting resistance to both cytotoxic and anti-EGFR therapy \[[@bb0095], [@bb0100], [@bb0105]\].

Mutations in genes other than those constituting the RAS/RAF pathway include PIK3CA and PTEN \[[@bb0110]\]. Approximately 15--20% of patients with mCRC, have mutations in exon 20 of PIK3CA and demonstrate resistance to cetuximab even in the presence of KRAS wild type \[[@bb0115]\]. Loss of expression of PTEN, a natural inhibitor of PI3K-initiated signalling, has itself also been associated with unresponsiveness to cetuximab and reduced OS \[[@bb0120],[@bb0125]\]. Beyond the factors associated with EGFR signalling pathways, a number of other genes are significantly mutated in CRC, including APC (51--81%), TP53 (20--60%), and SMAD4 (10--20%) \[[@bb0060]\]. APC is the most prevalent gene in the establishment of sporadic colorectal malignancy \[[@bb0130]\]. Similar to APC, the TP53 gene is heavily involved in the malignant transformation of CRC, with mutation in TP53 resulting in a non-functional p53 protein and reduced OS \[[@bb0135], [@bb0140], [@bb0145], [@bb0150]\]. Unlike APC and TP53, which usually occur in early colorectal tumorigenesis, inactivation of SMAD4 is associated with late-stage or metastatic disease \[[@bb0155]\]. SMAD4, also known as DPC4, encodes a tumour suppressor that regulates transcriptional activity downstream of TGF-beta receptor signalling. Expression of SMAD4 is an important prognostic factor in CRC, with patients who retain higher levels of SMAD4 within their tumours having higher OS than those with low or absent expression \[[@bb0160],[@bb0165]\].

This study aims to systematically review the literature and undertake meta-analysis where appropriate in order to determine the concordance between primary CRC and its metastatic site, with regards to the above-mentioned biomarkers and their combinations. It also aims to determine the variation in concordance by metastatic site, and the 'absolute concordance' in multiple biomarkers for mCRC. This is important for two reasons: First, it has implications for the understanding of how tumours evolve and differ between the primary and metastatic site. Studies demonstrating the dynamic changes in circulating DNA of mCRC patients with the clonal evolution and resistance to anti-EGFR treatments with time have suggested that the CRC genome adapts to drug schedules, providing a molecular explanation for changes in efficacy with re-challenge anti-EGFR therapies \[[@bb0170]\]. Second it also has implications for personalized treatment strategies used for patients based on single site biopsies \[[@bb0175],[@bb0180]\]. This study tries to shed light in respect to the heterogeneity (studied as mutational discordance) between the primary and metastatic sites in light of evidence that significant intra-tumour heterogeneity exists between different points on the same primary CRC specimen \[[@bb0185]\]. There are cases where the primary tumour cannot be accessed, in which case knowledge on concordance between the metastatic sites (liver, lung, lymph node or peritoneum) is important.

2. Methods {#s0025}
==========

This systematic review was undertaken in accordance with the PRISMA guidelines \[[@bb0190]\]. A literature search was undertaken by two independent reviewers (DB and OA) of all published studies using PubMed, MEDLINE, Ovid, Embase, Cochrane, and Google Scholar databases using the following MeSH terms: "colorectal neoplasm", "peritoneal neoplasm" and "mutation", plus additional search terms including: "primary colorectal cancer", "metastasis", "biomarker", and "concordance". Further references were identified manually using the bibliographies of relevant papers and review articles. Equal consideration was given to fully published studies and those available in only abstract form.

2.1. Study selection {#s0030}
--------------------

Studies were included provided that patients had a confirmed diagnosis of metastatic colorectal adenocarcinoma, and mutational biomarker analysis on biopsies both from the colorectal primary and at least one site of metastasis. Studies were excluded if the primary and metastatic tumour samples were unmatched, concordance was reported in relation to peripheral blood samples instead of solid tumour, or there was insufficient data available to provide a value for concordance. The method and extent of mutational analysis was not a criterion for exclusion. In this study the biomarker concordance between primary tumour and metastasis was defined in terms of both mutant and wild-type pairs, and not limited to the mutant-only population.

2.2. Meta-analysis {#s0035}
------------------

The proportion of changes (discordance proportion) with exact 95% confidence intervals (CIs) was calculated for each study. The Freeman--Tukey double arcsine transformation was the chosen approach for the calculation of pooled estimates and corresponding 95% CIs \[[@bb0195],[@bb0200]\]. If a study had a sample size below 10, the arcsine transformation was preferred. Random effects pooled estimates were calculated in order to take into account heterogeneity between estimates \[[@bb0205]\]. Statistical heterogeneity among studies was evaluated using the chi-square test statistic and was measured using the I^2^ statistic, which is the proportion of total variation contributed by between-study variance tau-squared (τ^2^) \[[@bb0210]\]. Publication bias was evaluated using funnel plots and the asymmetry test developed by Egger et al. \[[@bb0215]\]

All analyses were carried out with R software (<http://cran.r-project>.org/) with packages 'meta' and 'metafor'. All the reported *P* values were two sided.

3. Results {#s0040}
==========

Literature search identified 1498 studies reporting on concordance in mCRC between 1991 and 2018. Of these, 61 articles including 3565 patients matched the selection criteria and were deemed suitable for qualitative synthesis as outlined in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1PRISMA flow diagram of the literature search.Fig. 1

3.1. Concordance between primary CRC and its metastatic site {#s0045}
------------------------------------------------------------

Concordance in individual biomarker status in patients with mCRC was reported in a range of oncogenes and tumour suppressor genes. The median reported concordance was 93.7% (range 67--100) for KRAS (*n* = 50) \[[@bb0120],[@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250], [@bb0255], [@bb0260], [@bb0265], [@bb0270], [@bb0275], [@bb0280], [@bb0285], [@bb0290], [@bb0295], [@bb0300], [@bb0305], [@bb0310], [@bb0315], [@bb0320], [@bb0325], [@bb0330], [@bb0335], [@bb0340], [@bb0345], [@bb0350], [@bb0355], [@bb0360], [@bb0365], [@bb0370], [@bb0375], [@bb0380], [@bb0385], [@bb0390], [@bb0395], [@bb0400], [@bb0405], [@bb0410], [@bb0415], [@bb0420], [@bb0425], [@bb0430], [@bb0435], [@bb0440], [@bb0445], [@bb0450], [@bb0455], [@bb0460], [@bb0465]\], 99.4% (range 80--100) for BRAF (*n* = 22) \[[@bb0220],[@bb0225],[@bb0240],[@bb0245],[@bb0270],[@bb0300],[@bb0305],[@bb0315], [@bb0320], [@bb0325],[@bb0335], [@bb0340], [@bb0345],[@bb0355],[@bb0365], [@bb0370], [@bb0375], [@bb0380],[@bb0395],[@bb0400],[@bb0415],[@bb0430]\], 93% (range 42--100) for PIK3CA (*n* = 17) \[[@bb0220],[@bb0240], [@bb0245], [@bb0250], [@bb0255],[@bb0265],[@bb0270],[@bb0290], [@bb0295], [@bb0300],[@bb0315],[@bb0325],[@bb0335], [@bb0340], [@bb0345],[@bb0365],[@bb0380]\], 92.9% (range 73--100) for TP53 (*n* = 12) \[[@bb0220],[@bb0240],[@bb0255], [@bb0260], [@bb0265],[@bb0290], [@bb0295], [@bb0300],[@bb0315],[@bb0320],[@bb0340],[@bb0435]\], and 100% (range 90--100) for NRAS (*n* = 11) \[[@bb0220],[@bb0240],[@bb0245],[@bb0255],[@bb0280],[@bb0295],[@bb0300],[@bb0315],[@bb0340],[@bb0345],[@bb0465]\]. Less commonly reported markers included: PTEN (*n* = 10) \[[@bb0120],[@bb0220],[@bb0240],[@bb0265],[@bb0315],[@bb0335],[@bb0355],[@bb0380],[@bb0395],[@bb0470]\], APC (n = 10) \[[@bb0220],[@bb0240],[@bb0255], [@bb0260], [@bb0265],[@bb0290],[@bb0295],[@bb0315],[@bb0320],[@bb0440]\], SMAD4 (*n* = 6) \[[@bb0255],[@bb0265],[@bb0270],[@bb0290],[@bb0315],[@bb0320]\], and EGFR (*n* = 5) \[[@bb0120],[@bb0355],[@bb0395],[@bb0475],[@bb0480]\]. Additional data was also available on the concordance of MSI status and MMR genes (n = 5) \[[@bb0225],[@bb0240],[@bb0325],[@bb0485],[@bb0490]\]. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"} summarize the concordance rates for KRAS, BRAF, and PIK3CA, the three most commonly studied biomarkers.Table 1KRAS biomarker studies (*n* = 50).Table 1StudyYear*N*AnalysisCodonsSites of metastasisConcordance (%)Moorcraft et al.201715NGS--Lu92Fujiyoshi et al.2017457NGS12, 13, 61L + D96.9Petaccia de Macedo et al.201797Pyro12, 13, 61L + D97.9Pang et al.201772ARMS PCR--L + D81.9Nemecek et al.201612NGS12, 13, 22, 61, 117, 146L + D75Li et al.201658qRT-PCR + NGS12, 13D81He et al.201659PCR12, 13, 61, 117D76.3Kovaleva et al.201614NGS12, 13D78.6Crumley et al.201616NGS--L + D93.8Vignot et al.201513NGS--D100Jesinghaus et al.201524NGS--L + D100Siyar-Ekinci et al.201531Pyro--D77.4Lau et al.201582Sanger12, 13, 61D88.1Lee et al.201574Seq12, 13L + D79.7Lim et al.201534NGS + Sanger--Li97Kim et al.201519NGS12, 13, 61L + D100Kleist et al.2014151Seq12, 13, 61L + D86.8Giannini et al.201417PCR + Pyro12, 13L + D82.4Paliogiannis et al.201431Seq12, 13, 61D90.3Brannon et al.201469NGS--D100Lee et al.201415NGS--Li80Murata et al.201326Pyro12L + D94Miglio et al.201345Seq12, 13L + D100Vakiani et al.201284Sanger12, 13, 22, 61, 117, 146L + D97.6Vermaat et al.201221NGS + Sanger12, 13, 61, 146Li85.7Knijn et al.2011305Seq12, 13Li96.4Park et al.201117Seq12,13L + D76Watanabe et al.201143Seq12, 13D88.4Baldus et al.201075Pyro--L + D74.7Italiano et al.201064Seq----94.9Mariani et al.201038Seq12, 13D97Perrone et al.200912Seq12, 13D80Cejas et al.2009110Seq12, 13D94Garm-Spindler et al.200931qPCR12, 13D93.5Loupakis et al.200953Seq12, 13D95Molinari et al.200938Seq12, 13L + D92Gattenlöhner et al.200921AS-PCR12, 13L + D95Etienne-Grimaldi et al.200848PCR-RFLP12, 13Li100Santini et al.200899Seq12, 13D96Artale et al.200848Seq12, 13D94Gattenlohner et al.2008106Seq12, 13L + D99Weber et al.200738Seq12, 13Li94.7Oliveira et al.200728----L67.9Albanese et al.200430PCR-SSCP12, 13Li70Zauber et al.200342Seq12, 13L + D100Tórtola et al.200151SSCP + Seq12, 13BM70Al-Mulla et al.199858PCR ASO12, 13L + D87Suchy et al.1992109PCR ASO12--100Losi et al.199235AS-PCR12, 13L + D100Oudejans et al.199131Seq12, 13, 61D93.5[^2][^3][^4][^5][^6][^7][^8][^9]Table 2BRAF biomarker studies (*n* = 22).Table 2StudyYear*N*AnalysisCodonsSites of metastasisConcordance (%)Moorcraft et al.201715NGS--Lu100Fujiyoshi et al.2017457PCR-RFLP600L + D100Nemecek et al.201612NGS600L + D92Li et al.201610NGS--D80Jesinghaus et al.201524NGS--D100Lee et al.201415NGS--Li93.3Kleist et al.2014151PCR Seq--L + D98.7Giannini et al.201417PCR + Pyro600L + D94.1Brannon et al.201469NGS--D100Murata et al.201326Pyro600L + D100Voutsina et al.201383Sanger + ARMS AS-PCR600D100Vermaat et al.201221NGS + Sanger600Li100Vakiani et al.201284Sanger600L + D100Park et al.201120Seq600L + D90Mariani et al.201038Seq600D100Italiano et al.201048PCR Seq----97.9Baldus et al.201075Pyro600L + D97.4Perrone et al.200912PCR Seq600D90.1Molinari et al.200938PCR Seq600L + D100Gattenlöhner et al.200921AS-PCR600D100Artale et al.200848Seq600D98Oliveira et al.200728--600 + 601L89.3[^10][^11][^12][^13][^14][^15][^16][^17]Table 3PIK3CA biomarker studies (*n* = 17).Table 3StudyYear*N*AnalysisCodonsSite of metastasesConcordance (%)Moorcraft et al.201715NGS--Lu86.7Li et al.201610NGS--D100He et al.201659PCR Seq542, 545, 1047D42.4Kovaleva et al.201614NGS542, 545, 1047D92.9Nemecek et al.201612NGS542, 545, 1047L + D83Vignot et al.201513NGS--D100Jesinghaus et al.201524NGS--D100Lim et al.201534NGS + Sanger--Li100Kim et al.201519NGS542, 545, 1047L + D100Kleist et al.2014151PCR Seq542, 545, 1047L + D97.4Brannon et al.201469NGS--D94.2Murata et al.201332Pyro542, 545, 1047L + D88Voutsina et al.201383Sanger + ARMS AS-PCR525, 545, 1047D93Vakiani et al.201284Sanger345, 420, 542, 545, 546, 1043, 1047L + D98.8Vermaat et al.201221NGS + Sanger542, 545, 1047Li85.7Baldus et al.201075Pyro--L + D89.3Perrone et al.200912PCR Seq542, 545, 1047D90.1[^18][^19][^20][^21][^22][^23][^24][^25]

Other CRC biomarkers infrequently reported in the literature included AKT (*n* = 4, range 68--90%) \[[@bb0120],[@bb0240],[@bb0245],[@bb0260]\], CTNNB1 (n = 4, range 95--100%) \[[@bb0220],[@bb0240],[@bb0260],[@bb0270]\], MET (*n* = 3, range 75--100%) \[[@bb0240],[@bb0260],[@bb0335]\], and FBXW7 (n = 3, range 83--100%) \[[@bb0220],[@bb0240],[@bb0260]\]. Only two or fewer studies accounted for mutational concordance in the following genes: STK11, KIT, FGFR3, GNAQ, NOTCH, ATM, ARID1A, and FAT4, in addition to various others \[[@bb0220],[@bb0240],[@bb0255],[@bb0260],[@bb0270],[@bb0320]\]. This also included singular studies of mitochondrial microsatellite instability (mtMSI), CpG island methylator phenotype (CIMP), neuroendocrine differentiation, and microRNA (miRNA) \[[@bb0300],[@bb0495], [@bb0500], [@bb0505]\].

3.2. Concordance depending on metastatic site {#s0050}
---------------------------------------------

The liver was the most commonly included metastatic site within studies (*n* = 53 studies including 2276 patients), followed by the: lung (*n* = 37 studies including 438 patients), lymph nodes (*n* = 30 studies including 1123 patients), and peritoneum (*n* = 17 studies, including 132 patients). 27 studies analysed biomarker concordance separately within these metastatic sites as displayed in [Table 4](#t0020){ref-type="table"}, thus allowing comparison between metastatic location and the possible impact on concordance. Of these studies, 21 gave concordance data specific to liver metastases \[[@bb0220], [@bb0225], [@bb0230],[@bb0245], [@bb0250], [@bb0255],[@bb0265],[@bb0280],[@bb0305],[@bb0315], [@bb0320], [@bb0325],[@bb0345],[@bb0350],[@bb0360],[@bb0385],[@bb0400], [@bb0405], [@bb0410],[@bb0470],[@bb0500]\], 11 for lung metastases \[[@bb0190],[@bb0210],[@bb0245],[@bb0295],[@bb0300],[@bb0325],[@bb0340],[@bb0420], [@bb0425], [@bb0430], [@bb0435]\] and 12 for lymph nodes \[[@bb0230],[@bb0235],[@bb0245],[@bb0260],[@bb0285],[@bb0300],[@bb0305],[@bb0335],[@bb0340],[@bb0375],[@bb0420],[@bb0435]\]. Only two studies provided separate concordance for peritoneal metastases and likewise only single studies for ovarian and bone metastases were available, with most studies grouping these with other metastatic sites \[[@bb0225],[@bb0265],[@bb0315],[@bb0445]\].Table 4Concordance studies by metastatic type (*n* = 27).Table 4Biomarker concordance according to metastatic site (%)StudyYearBiomarkerLNLiverLungPTMOtherKleist et al.2017mtMSI2548Fujiyoshi et al.2017KRAS97.197.41009885.7BRAF100100100100100MSI/MSS98.8100-92100Moorcraft et al.2017KRAS10093100NRAS100100100BRAF100100100PIK3CA10086.7100100PTEN100100100TP53100100 80100100APCPetaccia et al.2017KRAS97.898.9100Crumley et al.2016KRAS92.3100TP5392.3100APC84.6100He et al.2016KRAS75.866.792.9PIK3CA39.444.447.1Kovaleva et al.2016KRAS85.785.7NRAS100100PIK3CA92.992.9TP5392.992.978.6APC71.4100SMAD492.9Li et al.2016KRAS1008080NRAS10010050BRAF080100PIK3CA100100100Vignot et al.2015KRAS100100PIK3CA100100PTEN100100TP5384.6100APC91.7100SMAD484.6100Lau et al.2015RAS10066.7Giannini et al.2014KRAS78.6100BRAF92.9100Kleist et al.2014KRAS88.183.3NRAS99.197.6BRAF99.1100PIK3CA96.3100TP5395.4100Brannon et al.2014KRAS100100NRAS100100BRAF100100PIK3CA98.5100PTEN100100TP53100100APC93.9100Lee et al.2014KRAS80BRAF93.3TP5373.3APC53.3SMAD493.3Atreya et al.2013PTEN98Murata et al.2013KRAS10094BRAF100100PIK3CA10088MSI10096Vermaat et al.2012KRAS85.7NRAS100BRAF100PIK3CA100Knijn et al.2011KRAS8096.4Watanabe et al.2011KRAS100100Baldus et al.2010KRAS6990BRAF96100PIK3CA8795Cejas et al.2009KRAS94.688.2Molinari et al.2009KRAS10092BRAF100100PTEN8789Etienne-Grimaldi et al.2008KRAS100Gattenlohner et al.2008KRAS98.69910096Santini et al.2008KRAS9680Oliveira et al.2007KRAS67.9BRAF89.3Tórtola et al.2001KRAS70[^26]

3.3. Absolute concordance {#s0055}
-------------------------

15 studies compared the overall molecular profiles of the matched primary and metastatic sites as shown in [Table 5](#t0025){ref-type="table"} \[[@bb0220],[@bb0225],[@bb0255],[@bb0260],[@bb0270],[@bb0295],[@bb0300],[@bb0315],[@bb0325],[@bb0345],[@bb0380],[@bb0400],[@bb0415],[@bb0465],[@bb0510]\]. An additional 2 studies reported on somatic variance between matched tumours \[[@bb0515],[@bb0520]\]. Studies identified that the greater the number of genes included within the analysis, the lower the rate of absolute concordance. For example, a combination of KRAS and BRAF was concordant in 44 out of 48 of cases (91.7%) but sequencing of \>1000 genes in a separate cohort saw concordance fall to only 1 in 19 cases (5.3%) \[[@bb0225],[@bb0360]\].Table 5Absolute concordance in all biomarkers (*n* = 15).Table 5StudyYear*N*SequencingBiomarkers includedSites of metastasesAbsolute (%) concordanceFujiyoshi et al.2017257NGSKRAS & BRAFLi, Lu, LN, PTM94.6Moorcraft et al.201715NGSKRAS, NRAS, BRAF, PIK3CA, PTEN, TP53, APC...Lu73Kovaleva et al.201614NGSKRAS, NRAS, PIK3CA, TP53, APC...Li, Lu57.1Crumley et al.201616NGSKRAS, TP53 & APCLN, Li, Lu81Jesinghaus et al.201524NGS - 12 genesKRAS, NRAS, BRAF, PIK3CA, PTEN, TP53, APC...LN, Li, Lu, Br84.4Kim et al.201519NGS - 1321 genesAPC, KRAS, TP53, BRAF, PIK3CA...LN, Li, Lu, Ov5Kleist et al.201442DNA PCRKRAS, NRAS, BRAF, PIK3CA & TP53Li, Abw, Ut, Ov, Va, PTM, OTM, SI81Brannon et al.201469NGS - 230 genesKRAS, NRAS, BRAF...Li, Lu, Ov31.9Murata et al.201332PyroKRAS, BRAF, PIK3CA & MSILN, Li84Vermaat et al.201221NGS + SangerKRAS, NRAS, BRAF, PIK3CA & EGFRLi85.7Balschun et al.20115Sanger + PyroKRAS, NRAS, BRAF, PIK3CA & MSILi20Perrone et al.200912PCRKRAS, BRAF, PI3KCA & PTENLi, Lu, Ut58.3Gattenlöhner et al.200921DNA PCR + AS-PCRKRAS & BRAFLN, Li, Lu, PTN, Mes, SI, ST95Artale et al.200848DNA PCRKRAS & BRAFLi, Lu, Ov, LN, Adr, Pan, OTM92Oudejans et al.199131DNA PCRRASLi, Lu87.1[^27]

3.4. Meta-analysis of the discordance {#s0060}
-------------------------------------

The discordance rate was assessed in 3066 patients for KRAS, 1312 patients for BRAF, 727 patients for PIK3CA and 626 patients with overall molecular profiles. There was no evidence for publication bias for PIK3CA and the overall molecular profiles (labelled as "ALL" in the [Supplementary Fig. 1](#f0030){ref-type="graphic"} (Egger\'s test: *p* = .76 and *p* = .08 respectively). However, publication bias was found in KRAS and BRAF studies (Egger\'s test: *p* = .01 and p = .01 respectively).(i)KRAS - [Fig. 2](#f0010){ref-type="fig"} shows the discordance proportions reported for KRAS in each study included in the analysis. The heterogeneity between proportions ranged from 0% to 29% (I^2^ = 91%, τ^2^ = 0.012, *p* \< .0001). The meta-analytic pooled discordance proportion was 8% (95% CI: 5--10%).Fig. 2Forest plot for proportion of discordance of KRAS. The estimate proportion and 95% CI interval at the level of the total number of cases reflects the calculation under a fixed effect model. The estimate proportion and 95% CI interval at the level of the Pooled Discordance Proportion are the random effects pooled estimates to take into account heterogeneity.Fig. 2(ii)BRAF - [Fig. 3](#f0015){ref-type="fig"} shows the discordance proportions reported for BRAF in each study included in the analysis. The heterogeneity between proportions ranged from 0% to 20% (I^2^ = 59%, τ^2^ = 0.007, *p* \< .0003). The meta-analytic pooled discordance proportion was 8% (95% CI: 5--10%).Fig. 3Forest plot for proportion of discordance of BRAF. The estimate proportion and 95% CI interval at the level of the total number of cases reflects the calculation under a fixed effect model. The estimate proportion and 95% CI interval at the level of the Pooled Discordance Proportion are the random effects pooled estimates to take into account heterogeneity.Fig. 3(iii)PIK3CA **-** [Fig. 4](#f0020){ref-type="fig"} shows the discordance proportions reported for PIK3CA in each study included in the analysis. The heterogeneity between proportions ranged from 0% to 58% (I^2^ = 86%, τ^2^ = 0.04, *p* \< .0001). The meta-analytic pooled discordance proportion was 7% (95% CI: 2--13%).Fig. 4Forest plot for proportion of discordance of PIK3CA. The estimate proportion and 95% CI interval at the level of the total number of cases reflects the calculation under a fixed effect model. The estimate proportion and 95% CI interval at the level of the Pooled Discordance Proportion are the random effects pooled estimates to take into account heterogeneity.Fig. 4(iv)Overall molecular profiles -- [Fig. 5](#f0025){ref-type="fig"} shows the discordance proportions reported considering the overall molecular profiles. PIK3CA in for all studies included in the analysis. The heterogeneity between proportions ranged from 5% to 95% (I^2^ = 93%, τ^2^ = 0.1, p \< .0001). The meta-analytic pooled discordance proportion was 28% (95% CI: 14--44%).Fig. 5Forest plot for proportion of discordance of studies considering the overall molecular profiles. The estimate proportion and 95% CI interval at the level of the total number of cases reflects the calculation under a fixed effect model. The estimate proportion and 95% CI interval at the level of the Pooled Discordance Proportion are the random effects pooled estimates to take into account heterogeneity.Fig. 5

4. Discussion {#s0065}
=============

A total of 9 studies reported absolute concordance in KRAS point mutations within codons 12 and 13, despite apparent differences in sequencing methodologies, suggesting the stability in KRAS status between the primary and metastatic sites \[[@bb0265],[@bb0270],[@bb0295],[@bb0315],[@bb0330],[@bb0405],[@bb0440],[@bb0455],[@bb0460]\]. Of note, Tórtola et al. did identify some discordance when using single-stand conformational polymorphism (SSCP) analysis of bone micrometastases \[[@bb0445]\]. In this study, 17 mutations were found among the primary tumours compared to only 7 in corresponding metastases, and whereas the majority (88%) of mutated KRAS in primary CRC\'s were located in codon 12, in the bone marrow these mutations were mainly localised to codon 13 (71%) \[[@bb0445]\]. There are however studies that identified discordance rates in KRAS as high as 30% \[[@bb0430],[@bb0435]\]. In the case of Baldus et al., the lower reported concordance was suggested to be attributable to intra-tumour heterogeneity; a phenomenon strongly evidenced in colorectal tumours as well as numerous other solid malignancies \[[@bb0185],[@bb0365],[@bb0525],[@bb0530]\]. In a comparable study by He et al., a combination of low sensitivity testing and unrepeated mutation analysis of the tissues could have led to false-negatives \[[@bb0250],[@bb0365]\]. This is effectively illustrated in the study by Vakiani and colleagues where concordance rates increased by 5% when more sensitive analysis methods were used \[[@bb0340]\]. KRAS status can therefore be determined from the primary tumour or the metastatic site as long as the sample is sufficient and sequencing technique adequate.

Although significantly fewer studies have evaluated NRAS status compared to KRAS in matched tumours, the available data suggests concordance rates are also high (median of 100%, range 90--100%) regardless of sequencing method \[[@bb0280],[@bb0300],[@bb0315]\]. BRAF notably demonstrated 100% mutation concordance in half of the identified studies, despite similar variances in the type of metastasis sampled and sequencing method \[[@bb0240],[@bb0270],[@bb0325],[@bb0340]\]. Expanded analysis of BRAF mutations to include exons 11 and 15 did result in a slightly lower concordance (median of 99.4%, range 80--100%), with discordance limited to V600E region of exon 15 \[[@bb0380]\]. It is important to note that all of the studies reporting lower rates of BRAF concordance demonstrated a small sample size of paired specimens which may have impacted their results. This is aligned to the publication bias detected in this particular subset where usually smaller studies are published only with positive findings. Altogether 7 BRAF studies had sample sizes that were considered small, defined as less than or equal to 20 matched patient samples \[[@bb0245],[@bb0355],[@bb0380]\].

The results for PIK3CA in some cases show a much more discordant relationship between the primary tumour and the metastasis, with a median concordance of 93% (42--100%) \[[@bb0250]\]. While the aforementioned report is unhindered by its adequate sample size (\>50 matched pairs), a combination of the low sensitivity method of sequencing within this study and the unusually high proportion of patients with detected PIK3CA mutation may somewhat explain its contradiction to the rest of the literature \[[@bb0250]\]. Thus, based on the consistent results of other studies, the concordance rate for PIK3CA is relatively high overall within the average CRC population \[[@bb0300],[@bb0315],[@bb0365]\]. Importantly, this study identified that some of the tumour suppressor genes (PTEN, TP53, APC and SMAD4) can show a more variable and discordant relationship between the primary tumour and the metastasis \[[@bb0295]\]. Mutation within these tumour suppressors, such as TP53, is at times more common in the metastasis than the primary \[[@bb0340]\]. However, cumulative data indicate that the PTEN and APC genes are among those demonstrating the greatest variation, revealing less consistency for higher rates of concordance \[[@bb0120],[@bb0255],[@bb0260],[@bb0315],[@bb0320],[@bb0335],[@bb0470]\]. We also found that although primary tumours and their metastases displayed a variable concordance with regards to MSI and EGFR, the number of studies reporting on these biomarkers was small making our findings difficult to interpret \[[@bb0120],[@bb0225],[@bb0475],[@bb0485]\]. Nonetheless, EGFR does show notable evidence of a predisposition toward discordant expression \[[@bb0475],[@bb0480]\].

This study was also able to determine biomarker concordance by metastatic site, with hepatic metastases most commonly studied and displaying a remarkably concordant relationship with the primary tumour \[[@bb0315],[@bb0345]\]. The liver is a site that can be relatively easily biopsied with sufficient sample sizes (core biopsies). In contrast, pulmonary metastases are more challenging to sample and therefore not surprisingly were sampled less frequently than the liver. Much of the variation in concordance with lung metastases may be explained by this. It is however a valid site for biopsy and determination of RAS status. Peritoneal samples were extremely infrequently sampled and would also be potentially more difficult to obtain sufficient tissue from due to their location and size. It is therefore difficult to comment on their relationship with the primary. Only two studies reported on biomarker concordance specifically comparing peritoneal metastases to the primary tumour \[[@bb0225],[@bb0265]\]. This suggests the need to investigate this area, particularly as peritoneal metastases have a significantly worse median OS (16.3 months) compared to liver (19.1 months) and lung (24.6 months) metastases \[[@bb0535]\].

It is not surprising that we found that absolute concordance in more than one biomarker fell as the number of biomarkers was increased. For example limiting analysis to KRAS and BRAF demonstrated a 92--95% concordance \[[@bb0225],[@bb0400],[@bb0415]\], falling to 87% with extended RAS mutation analysis (including KRAS, NRAS and HRAS) \[[@bb0465]\]. Cohorts tested for KRAS and BRAF as well as additional alterations in PIK3CA/PTEN/TP53/APC demonstrate a more variable absolute concordance ranging from 57 to 84% \[[@bb0220],[@bb0255],[@bb0270]\]. Finally studies comparing 12, 230 and 1321 gene sequencing have demonstrated how absolute concordance falls as more genes are included within the analysis to only 5% \[[@bb0295],[@bb0315],[@bb0540]\]. This suggests that the metastases are distinctly different in their genetic composition to the primary tumour \[[@bb0320]\]. In any case poor absolute concordance may provide some explanation as to the complexities of colorectal tumours and their resistance to cytotoxic and biological therapies \[[@bb0545]\]. Furthermore, as metastases generally possess greater mutational load than primary tumours as well as less intra-tumour heterogeneity, basing clinical decision-making on the profile of metastases in preference to generalising the data obtained from primary tumours may be beneficial \[[@bb0320],[@bb0335]\].

It is important to note a number of limitations of this study. First it should be noted that the studies included were retrospective and varied in their sample size. This was reflected in the meta-analysis showing a clear publication bias for the KRAS and BRAF papers. Second, there was heterogeneity in sample collection and processing techniques as well as sequencing techniques used which have evolved over time, making absolute comparisons difficult. This would for example explain the higher concordance for newer biomarkers such as NRAS. Third, the patients varied in the systemic treatments they received, and the impact of this on the metastasis (tumour regression after chemo- or radiotherapy) may have affected the sequencing result through adequacy of the sample. Fourth, it is important to note that any change in concordance may represent the evolution of the tumour as it metastasises and therefore the time between the primary tumour and metastasis sampling is an important factor to consider which could not be accounted for. Finally inter-tumour heterogeneity means that sufficient samples may not have been possible to obtain in many of the studies to determine biomarker status especially at the metastatic sites.

Despite the above limitations, we feel that this study has demonstrated high biomarker concordance rate between primary tumours and the metastases with challenges in getting adequate sample size from metastatic sites likely to account for most discordance. This has important practical implications as it suggests there is little evidence for separate biopsy of the primary and metastatic sites. Whether the evolving use of liquid biopsy through circulating tumour DNA (ctDNA) analysis adds anything further to a patient\'s treatment options remains to be seen. We also feel that little information is currently available on peritoneal metastases and this is an area for further research.

5. Conclusion {#s0070}
=============

mCRC demonstrates remarkably high concordance across a number of individual biomarkers, suggesting that molecular testing of either the primary or liver and lung metastasis is adequate for determining biomarker status to personalize treatment. More research is required to determine concordance in colorectal cancer peritoneal metastases which may explain why these tumours have a significantly worse prognosis compared to other sites. Clonal selection and tumour evolution add further inherent complexities that may be addressed through new sampling strategies and novel technologies in development.

The following are the supplementary data related to this article.Supplementary Fig. 1Funnel plots to study the publication bias of all the subsets analysed. "ALL" labels the studies considering the overall molecular profiles. *P*-values for asymmetry obtained by the method developed by Egger and colleagues.Supplementary Fig. 1
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